American Association for Cancer Research
Browse
00085472can171915-sup-185454_2_supp_4269983_cwcgdc.docx (14.11 kB)

Table S3 from Mesenchymal Stem Cells Promote Hepatocarcinogenesis via lncRNA–MUF Interaction with ANXA2 and miR-34a

Download (14.11 kB)
journal contribution
posted on 2023-03-31, 01:06 authored by Xinlong Yan, Dongdong Zhang, Wei Wu, Shuheng Wu, Jingfeng Qian, Yajing Hao, Fang Yan, Pingping Zhu, Jiayi Wu, Guanling Huang, Yinghui Huang, Jianjun Luo, Xinhui Liu, Benyu Liu, Xiaomin Chen, Ying Du, Runsheng Chen, Zusen Fan

RNA pulldown assays followed by mass spectrum indicated that lncRNA-MUF can bind with ANXA2.

Funding

National Natural Science Foundation of China

Beijing Natural Science Foundation

Beijing Municipal Education Commission

Program of the MOST of China

National High Technology Research and Development Program of China

History

ARTICLE ABSTRACT

Accumulating evidence suggests that cancer-associated mesenchymal stem cells (MSC) contribute to the development and metastasis of hepatocellular carcinoma (HCC). Aberrant expression of long noncoding RNAs (lncRNA) has been associated with these processes but cellular mechanisms are obscure. In this study, we report that HCC-associated mesenchymal stem cells (HCC-MSC) promote epithelial–mesenchymal transition (EMT) and liver tumorigenesis. We identified a novel lncRNA that we termed lncRNA–MUF (MSC-upregulated factor) that is highly expressed in HCC tissues and correlated with poor prognosis. Depleting lncRNA–MUF in HCC cells repressed EMT and inhibited their tumorigenic potential. Conversely, lncRNA–MUF overexpression accelerated EMT and malignant capacity. Mechanistic investigations showed that lncRNA–MUF bound Annexin A2 (ANXA2) and activated Wnt/β-catenin signaling and EMT. Furthermore, lncRNA-MUF acted as a competing endogenous RNA for miR-34a, leading to Snail1 upregulation and EMT activation. Collectively, our findings establish a lncRNA-mediated process in MSC that facilitates hepatocarcinogenesis, with potential implications for therapeutic targeting. Cancer Res; 77(23); 6704–16. ©2017 AACR.

Usage metrics

    Cancer Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC